On September 5, 2023, Autolus Therapeutics made an exciting announcement regarding the publication of data from the AUTO1/22 Phase 1 study (CARPALL) in Pediatric B-cell Acute Lymphoblastic Leukemia. This groundbreaking study has been published in the prestigious journal Blood, further solidifying its importance in the medical community.
Previously, the study was presented at the European Society for Blood and Marrow Transplantation in April 2023, garnering significant attention and interest from experts in the field. The primary objective of the study was to evaluate the safety and biological efficacy of AUTO1/22 in children and young adults suffering from relapsed or refractory acute lymphoblastic leukemia (ALL).
The results of the study were nothing short of remarkable, offering hope to patients who were ineligible for commercial CAR T therapy. An impressive 83% of patients achieved MRD negative, indicating a significant reduction in disease burden. This outcome is particularly encouraging as it demonstrates the potential of AUTO1/22 as an effective treatment option for those who have exhausted other available therapies.
The publication of these findings in Blood marks a significant milestone for Autolus Therapeutics and the field of pediatric oncology. The study’s success highlights the importance of continued research and innovation in the pursuit of improved treatments for acute lymphoblastic leukemia.
Autolus Therapeutics plc
Updated on: 07/12/2023
Debt to equity ratio: Buy
Price to earnings ratio: Sell
Price to book ratio: Buy
DCF: Strong Buy
12:00 PM (UTC)
Date:07 December, 2023
There are no analysts data to display
Urogen Pharma Ltd: Impressive Performance and Growth in 2023
On September 5, 2023, AUTL stock showed a positive performance. The stock opened at $3.17 and fluctuated between $3.17 and $3.41 throughout the day. The trading volume for the day was 356,647 shares. Urogen Pharma Ltd has a market capitalization of $579.2 million. The company has shown impressive earnings growth in the past year, with a growth rate of 20.52%. The current year’s earnings growth is even more impressive, at 44.70%. In terms of revenue growth, Urogen Pharma Ltd has experienced a significant increase of 311.02% in the last year. The P/E ratio for the stock is not available (NM). The price/sales ratio for Urogen Pharma Ltd is 29.14 and the price/book ratio is 2.93. On September 5, 2023, AUTL stock showed a positive change of $0.66, or 3.78%. Urogen Pharma Ltd’s performance on September 5, 2023, was better than Agenus Inc, which had a minimal increase of $0.01, or 0.72%. Alpine Immune Sciences Inc showed a larger increase of $0.55, or 4.45%. Urogen Pharma Ltd is a biotechnology company based in London, Greater London.
Autolus Therapeutics PLC Stock Shows Positive Performance and Promising Future Growth: Analysts Price Forecasts and Consensus Buy Rating
AUTL stock had a positive performance on September 5, 2023. The 10 analysts offering 12-month price forecasts for Autolus Therapeutics PLC had a median target of 6.50, with a high estimate of 12.00 and a low estimate of 2.80. This median estimate represents a significant increase of 94.61% from the last price of 3.34.
The consensus among 11 polled investment analysts is to buy stock in Autolus Therapeutics PLC. This rating has held steady since May.
Autolus Therapeutics PLC reported earnings per share of -$0.23 for the current quarter. It is important to consider the context of the company’s operations and the potential for future growth.
Autolus Therapeutics PLC reported sales of $473.2K for the current quarter. Many biotech companies experience low sales in the early stages as they focus on research and development.
Investors should keep an eye on Autolus Therapeutics PLC’s upcoming reporting date of November 9th. This will provide further insights into the company’s financial performance and potential future growth.
Overall, based on the analysts’ price forecasts and the consensus buy rating, Autolus Therapeutics PLC appears to have a positive outlook. Investors should carefully consider their own risk tolerance and conduct thorough research before making any investment decisions.